Fan Kailing, Hu Qingqing, Yu Shijun, Gao Yong, Li Yandong
Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Research Center for Translational Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
J Cancer. 2024 Jan 20;15(5):1355-1365. doi: 10.7150/jca.83812. eCollection 2024.
PIK3CB, one of catalytic subunits of PI3Ks kinase family, is implicated in several cellular processes such as cell growth, proliferation, mobility and neoplastic transformation. Its abnormal expression has been found in several human cancer types. However, the regulation pattern and function of PIK3CB in gastric cancer (GC) are still unclear. Here, we demonstrated that PIK3CB and SP1 (special protein 1) were both upregulated in GC samples compared to adjacent non-cancerous stomach tissues at mRNA and protein levels. The expression of the two genes also displayed a significant positive correlation in GC samples. Dual-luciferase assays and chromatin immunoprecipitation (ChIP) assays revealed that SP1 could bind to the -771~-605 region of the promoter of PIK3CB and enhance transcription. Furthermore, we discovered that SP1 induced AKT activation through PIK3CB and accelerated GC cell proliferation and migration in a PIK3CB/AKT signaling dependent manner. TGX-221, a PIK3CB-selective inhibitor, which can block this signaling transduction pathway, was found to inhibit the growth of GC cells and induce apoptosis , implying that it may act as a potential development agent for GC. These collective findings provide a new insight into PI3K/AKT signaling that SP1 may function as an upstream factor on PI3K, forming a new signaling axis to promote the progression of GC or other malignancies.
PIK3CB是PI3K激酶家族的催化亚基之一,参与细胞生长、增殖、迁移和肿瘤转化等多种细胞过程。在几种人类癌症类型中都发现了其异常表达。然而,PIK3CB在胃癌(GC)中的调控模式和功能仍不清楚。在此,我们证明,与相邻的非癌胃组织相比,PIK3CB和SP1(特殊蛋白1)在GC样本中的mRNA和蛋白质水平均上调。这两个基因的表达在GC样本中也显示出显著的正相关。双荧光素酶报告基因检测和染色质免疫沉淀(ChIP)检测表明,SP1可以结合PIK3CB启动子的-771~-605区域并增强转录。此外,我们发现SP1通过PIK3CB诱导AKT激活,并以PIK3CB/AKT信号依赖的方式加速GC细胞的增殖和迁移。TGX-221是一种PIK3CB选择性抑制剂,可阻断该信号转导途径,被发现能抑制GC细胞的生长并诱导凋亡,这意味着它可能作为GC的一种潜在开发药物。这些研究结果为PI3K/AKT信号传导提供了新的见解,即SP1可能作为PI3K的上游因子发挥作用,形成一个新的信号轴来促进GC或其他恶性肿瘤的进展。